Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Injectafer Rejected For First-Line Use; Promising For Second-Line, Panel Says

Executive Summary

Luitpold's Injectafer should be reserved for second-line use for treatment of iron deficiency anemia in postpartum patients and those with heavy uterine bleeding, FDA's Drug Safety and Risk Management Advisory Committee recommended Feb. 1

You may also be interested in...



Drug Approval News, In Brief

FDA’s recent actions include approval for Horizon’s Rayos delayed-release prednisone and “complete response” letters for two other drugs – Otsuka/Lundbeck’s depot injection of the atypical antipsychotic aripiprazole and Luitpold’s iron deficiency anemia treatment Injectafer.

Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Related Content

UsernamePublicRestriction

Register

PS049290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel